Abstract
Objective Assess in a sample of patients with type 1 diabetes mellitus whether mood and stress influence blood glucose levels and variability.
Material and Methods Continuous glucose monitoring was performed on 10 patients with type 1 diabetes, where interstitial glucose values were recorded every 15 minutes. A daily survey was conducted through Google Forms, collecting information on mood and stress. The day was divided into 6 slots of 4-hour each, asking the patient to assess each slot in relation to mood (sad, normal or happy) and stress (calm, normal or nervous). Different measures of glycemic control (arithmetic mean and percentage of time below/above the target range) and variability (standard deviation, percentage coefficient of variation, mean amplitude of glycemic excursions and mean of daily differences) were calculated to relate the mood and stress perceived by patients with blood glucose levels and glycemic variability. A hypothesis test was carried out to quantitatively compare the data groups of the different measures using the Student’s t-test.
Results Statistically significant differences (p-value < 0.05) were found between different levels of stress. In general, average glucose and variability decrease when the patient is calm. There are statistically significant differences (p-value < 0.05) between different levels of mood. Variability increases when the mood changes from sad to happy. However, the patient’s average glucose decreases as the mood improves.
Conclusions Variations in mood and stress significantly influence blood glucose levels, and glycemic variability in the patients analyzed with type 1 diabetes mellitus. Therefore, they are factors to consider for improving glycemic control. The mean of daily differences does not seem to be a good indicator for variability.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Fundación Eugenio Rodríguez Pascual 2019-2020. Ministerio de Economía y Competitividad under grant TIN2014-54806-R. Ministerio de Ciencia, Innovación y Universidades under grant RTI2018-095180-B-I00. Comunidad de Madrid under grants B2017/BMD3773 (GenObIA-CM) and Y2018/NMT-4668 (Micro-Stress-MAP-CM). European Union through structural and FEDER Funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Hospital Universitario Príncipe de Asturias, Alcála de Henares, Madrid, Spain. Project identification code: GANIMEDES-HERACLES, on April 2013.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data of the patients is not publicly available. It could be available on demand and after signing a Non Discluser Agreement.
